Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Heart Failure Reports
Erschienen in: Current Heart Failure Reports 6/2022

30.09.2022 | Clinical Heart Failure (T.E. Meyer, Section Editor)

Defining the Phenotypes for Heart Failure With Preserved Ejection Fraction

verfasst von: Dane Rucker, Jacob Joseph

Erschienen in: Current Heart Failure Reports | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Heart failure with preserved ejection fraction (HFpEF) imposes a significant burden on society and healthcare. The lack in efficacious therapies is likely due to the significant heterogeneity of HFpEF. In this review, we define various phenotypes based on underlying comorbidities or etiologies, discuss phenotypes arrived at by novel methods, and explore therapeutic targets.

Recent Findings

A few studies have used machine learning methods to uncover sub-phenotypes within HFpEF in an unbiased manner based on clinical features, echocardiographic findings, and biomarker levels.

Summary

We synthesized the literature and propose three broad phenotypes: (1) young, with few comorbidities, usually obese and with low natriuretic peptide levels, (2) obese with substantive cardiometabolic burden and comorbidities and impaired ventricular relaxation, (3) old, multimorbid, with high rates of atrial fibrillation, renal and coronary artery disease, chronic obstructive pulmonary disease, and left ventricular hypertrophy. We also propose potential therapeutic strategies for these phenotypes.
Literatur
1.
Heidenreich PA, Fonarow GC, Opsha Y, Sandhu AT, Sweitzer NK, Warraich HJ, et al. Economic issues in heart failure in the United States. J Card Fail. 2022;28(3):453–66.PubMedCrossRef
2.
Ferreira JP, Metra M, Mordi I, Gregson J, Ter Maaten JM, Tromp J, et al. Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-CHF study. Eur J Heart Fail. 2019;21(1):112–20.PubMedCrossRef
3.
Vasan RS, Xanthakis V, Lyass A, Andersson C, Tsao C, Cheng S, et al. Epidemiology of left ventricular systolic dysfunction and heart failure in the Framingham Study: an echocardiographic study over 3 decades. JACC Cardiovasc Imaging. 2018;11(1):1–11.PubMedCrossRef
4.
Chang PP, Wruck LM, Shahar E, Rossi JS, Loehr LR, Russell SD, et al. Trends in hospitalizations and survival of acute decompensated heart failure in four US communities (2005–2014): ARIC Study Community Surveillance. Circulation. 2018;138(1):12–24.PubMedPubMedCentralCrossRef
5.
• Cohen JB, Schrauben SJ, Zhao L, Basso MD, Cvijic ME, Li Z, et al. Clinical phenogroups in heart failure with preserved ejection fraction: detailed phenotypes, prognosis, and response to spironolactone. JACC Heart Fail. 2020;8(3):172–84. Provide initial LCA for HFpEF phenotyping using a multitude of biomarkers found previously to be associated with HFpEF.PubMedPubMedCentralCrossRef
6.
Kao DP, Lewsey JD, Anand IS, Massie BM, Zile MR, Carson PE, et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. Eur J Heart Fail. 2015;17(9):925–35.PubMedCrossRef
7.
Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(22):2872–91.PubMedPubMedCentralCrossRef
8.
Emdin M, Aimo A, Rapezzi C, Fontana M, Perfetto F, Seferović PM, et al. Treatment of cardiac transthyretin amyloidosis: an update. Eur Heart J. 2019;40(45):3699–706.PubMedCrossRef
9.
Oghina S, Bougouin W, Bézard M, Kharoubi M, Komajda M, Cohen-Solal A, et al. The impact of patients with cardiac amyloidosis in HFpEF trials. JACC Heart Fail. 2021;9(3):169–78.PubMedCrossRef
10.
11.
Schmidt T, Frerker C. Treatment challenges in patients with acute heart failure and severe aortic valve stenosis. Curr Cardiol Rep. 2019;21(6):47.PubMedCrossRef
12.
Bachmann JC, Baumgart SJ, Uryga AK, Bosteen MH, Borghetti G, Nyberg M, et al. Fibrotic signaling in cardiac fibroblasts and vascular smooth muscle cells: the dual roles of fibrosis in HFpEF and CAD. Cells. 2022;11(10):1657. https://​doi.​org/​10.​3390/​cells11101657.
13.
Rao VN, Fudim M, Mentz RJ, Michos ED, Felker GM. Regional adiposity and heart failure with preserved ejection fraction. Eur J Heart Fail. 2020;22(9):1540–50.PubMedCrossRef
14.
15.
Sabbatini AR, Kararigas G. Menopause-related estrogen decrease and the pathogenesis of HFpEF: JACC review topic of the week. J Am Coll Cardiol. 2020;75(9):1074–82.PubMedCrossRef
16.
Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, Lee A, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13–27.PubMedCrossRef
17.
Reddy YNV, Obokata M, Verbrugge FH, Lin G, Borlaug BA. Atrial dysfunction in patients with heart failure with preserved ejection fraction and atrial fibrillation. J Am Coll Cardiol. 2020;76(9):1051–64.PubMedPubMedCentralCrossRef
18.
Harada T, Obokata M. Obesity-related heart failure with preserved ejection fraction: pathophysiology, diagnosis, and potential therapies. Heart Fail Clin. 2020;16(3):357–68.PubMedCrossRef
19.
Tromp J, Teng TH, Tay WT, Hung CL, Narasimhan C, Shimizu W, et al. Heart failure with preserved ejection fraction in Asia. Eur J Heart Fail. 2019;21(1):23–36.PubMedCrossRef
20.
Rajadurai J, Tse HF, Wang CH, Yang NI, Zhou J, Sim D. Understanding the epidemiology of heart failure to improve management practices: an Asia-Pacific perspective. J Card Fail. 2017;23(4):327–39.PubMedCrossRef
21.
Chandramouli C, Tay WT, Bamadhaj NS, Tromp J, Teng TK, Yap JJL, et al. Association of obesity with heart failure outcomes in 11 Asian regions: a cohort study. PLoS Med. 2019;16(9):e1002916.PubMedPubMedCentralCrossRef
22.
Kadowaki S, Miura K, Kadowaki T, Fujiyoshi A, El-Saed A, Masaki KH, et al. International comparison of abdominal fat distribution among four populations: the ERA-JUMP Study. Metab Syndr Relat Disord. 2018;16(4):166–73.PubMedPubMedCentralCrossRef
23.
24.
Wu CK, Tsai HY, Su MM, Wu YF, Hwang JJ, Lin JL, et al. Evolutional change in epicardial fat and its correlation with myocardial diffuse fibrosis in heart failure patients. J Clin Lipidol. 2017;11(6):1421–31.PubMedCrossRef
25.
Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation. 2017;136(1):6–19.PubMedPubMedCentralCrossRef
26.
Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015;116(6):991–1006.PubMedPubMedCentralCrossRef
27.
Sanderson JE, Fang F, Lu M, Ma CY, Wei YX. Obstructive sleep apnoea, intermittent hypoxia and heart failure with a preserved ejection fraction. Heart. 2021;107(3):190–4.PubMedCrossRef
28.
Ghio S, Raineri C, Scelsi L, Ašanin M, Polovina M, Seferovic P. Pulmonary hypertension and right ventricular remodeling in HFpEF and HFrEF. Heart Fail Rev. 2020;25(1):85–91.PubMedCrossRef
29.
Fayyaz AU, Edwards WD, Maleszewski JJ, Konik EA, DuBrock HM, Borlaug BA, et al. Global pulmonary vascular remodeling in pulmonary hypertension associated with heart failure and preserved or reduced ejection fraction. Circulation. 2018;137(17):1796–810.PubMedCrossRef
30.
Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013;309(12):1268–77.PubMedCrossRef
31.
32.
33.
Chávez-Iñiguez JS, Sánchez-Villaseca SJ, García-Macías LA. Cardiorenal syndrome: classification, pathophysiology, diagnosis and management. Literature review. Arch Cardiol Mex. 2022;92(2):253–63.PubMed
34.
Löfman I, Szummer K, Dahlström U, Jernberg T, Lund LH. Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction. Eur J Heart Fail. 2017;19(12):1606–14.PubMedCrossRef
35.
Kottgen A, Russell SD, Loehr LR, Crainiceanu CM, Rosamond WD, Chang PP, et al. Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol. 2007;18(4):1307–15.PubMedCrossRef
36.
McAlister FA, Ezekowitz J, Tarantini L, Squire I, Komajda M, Bayes-Genis A, et al. Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction: impact of the new Chronic Kidney Disease-Epidemiology Collaboration Group formula. Circ Heart Fail. 2012;5(3):309–14.PubMedCrossRef
37.
Ogawa T, Nitta K. Clinical impact of left ventricular diastolic dysfunction in chronic kidney disease. Contrib Nephrol. 2018;195:81–91.PubMedCrossRef
38.
Gori M, Senni M, Gupta DK, Charytan DM, Kraigher-Krainer E, Pieske B, et al. Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. Eur Heart J. 2014;35(48):3442–51.PubMedPubMedCentralCrossRef
39.
Glovaci D, Fan W, Wong ND. Epidemiology of diabetes mellitus and cardiovascular disease. Curr Cardiol Rep. 2019;21(4):21.PubMedCrossRef
40.
41.
van Melle JP, Bot M, de Jonge P, de Boer RA, van Veldhuisen DJ, Whooley MA. Diabetes, glycemic control, and new-onset heart failure in patients with stable coronary artery disease: data from the heart and soul study. Diabetes Care. 2010;33(9):2084–9.PubMedPubMedCentralCrossRef
42.
Rendra E, Riabov V, Mossel DM, Sevastyanova T, Harmsen MC, Kzhyshkowska J. Reactive oxygen species (ROS) in macrophage activation and function in diabetes. Immunobiology. 2019;224(2):242–53.PubMedCrossRef
43.
Nishi T, Saito Y, Kitahara H, Fujimoto Y, Kobayashi Y. Coronary flow reserve and glycemic variability in patients with coronary artery disease. Intern Med. 2021;60(8):1151–8.PubMedCrossRef
44.
Stanton AM, Vaduganathan M, Chang LS, Turchin A, Januzzi JL, Aroda VR. Asymptomatic diabetic cardiomyopathy: an underrecognized entity in type 2 diabetes. Curr Diab Rep. 2021;21(10):41.PubMedCrossRef
45.
Streng KW, Nauta JF, Hillege HL, Anker SD, Cleland JG, Dickstein K, et al. Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. Int J Cardiol. 2018;271:132–9.PubMedCrossRef
46.
Stringer WW. Are we treating heart failure in patients with chronic obstructive pulmonary disease appropriately? Ann Am Thorac Soc. 2020;17(8):932–4.PubMedPubMedCentralCrossRef
47.
Jain S, Obeid MJ, Yenigalla S, Paravathaneni M, Gadela NV, Singh G, et al. Impact of chronic obstructive pulmonary disease in heart failure with preserved ejection fraction. Am J Cardiol. 2021;149:47–56.PubMedCrossRef
48.
Gulea C, Zakeri R, Quint JK. Differences in outcomes between heart failure phenotypes in patients with coexistent chronic obstructive pulmonary disease: a cohort study. Ann Am Thorac Soc. 2022;19(6):971–80.PubMedCrossRef
49.
Huang WM, Feng JY, Cheng HM, Chen SZ, Huang CJ, Guo CY, et al. The role of pulmonary function in patients with heart failure and preserved ejection fraction: looking beyond chronic obstructive pulmonary disease. PLoS ONE. 2020;15(7):e0235152.PubMedPubMedCentralCrossRef
50.
Hwang SJ, Melenovsky V, Borlaug BA. Implications of coronary artery disease in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2014;63(25 Pt A):2817–27.PubMedCrossRef
51.
Rush CJ, Berry C, Oldroyd KG, Rocchiccioli JP, Lindsay MM, Touyz RM, et al. Prevalence of coronary artery disease and coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. JAMA Cardiol. 2021;6(10):1130–43.PubMedCrossRef
52.
Del Buono MG, Montone RA, Camilli M, Carbone S, Narula J, Lavie CJ, et al. Coronary microvascular dysfunction across the spectrum of cardiovascular diseases: JACC state-of-the-art review. J Am Coll Cardiol. 2021;78(13):1352–71.PubMedPubMedCentralCrossRef
53.
Shah SJ, Lam CSP, Svedlund S, Saraste A, Hage C, Tan RS, et al. Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. Eur Heart J. 2018;39(37):3439–50.PubMedPubMedCentralCrossRef
54.
Nelson MD, Wei J, Bairey Merz CN. Coronary microvascular dysfunction and heart failure with preserved ejection fraction as female-pattern cardiovascular disease: the chicken or the egg? Eur Heart J. 2018;39(10):850–2.PubMedPubMedCentralCrossRef
55.
Leong D, Tjoe B, Zarrini P, Cook-Wiens G, Wei J, Shufelt CL, et al. Risk factors for heart failure in women with ischemia and no obstructive coronary artery disease. AHJ Plus: Cardiology Research and Practice. 2021;8:100035.
56.
Taqueti VR, Solomon SD, Shah AM, Desai AS, Groarke JD, Osborne MT, et al. Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction. Eur Heart J. 2018;39(10):840–9.PubMedCrossRef
57.
Sanders-van Wijk S, van Empel V, Davarzani N, Maeder MT, Handschin R, Pfisterer ME, et al. Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction. Eur J Heart Fail. 2015;17(10):1006–14.PubMedCrossRef
58.
López-Vilella R, Lozano-Edo S, Arenas Martín P, Jover-Pastor P, Ezzitouny M, Sorolla Romero J, et al. Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction. ESC Heart Fail. 2022;9(1):133–45.PubMedCrossRef
59.
Chamsi-Pasha MA, Zhan Y, Debs D, Shah DJ. CMR in the evaluation of diastolic dysfunction and phenotyping of HFpEF: current role and future perspectives. JACC Cardiovasc Imaging. 2020;13(1 Pt 2):283–96.PubMedCrossRef
60.
Borlaug BA. Evaluation and management of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2020;17(9):559–73.PubMedCrossRef
61.
62.
Obokata M, Reddy YNV, Borlaug BA. Diastolic dysfunction and heart failure with preserved ejection fraction: understanding mechanisms by using noninvasive methods. JACC Cardiovasc Imaging. 2020;13(1 Pt 2):245–57.PubMedCrossRef
63.
64.
Zile MR, Gottdiener JS, Hetzel SJ, McMurray JJ, Komajda M, McKelvie R, et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation. 2011;124(23):2491–501.PubMedCrossRef
65.
Hung CL, Yun CH, Lai YH, Sung KT, Bezerra HG, Kuo JY, et al. An observational study of the association among interatrial adiposity by computed tomography measure, insulin resistance, and left atrial electromechanical disturbances in heart failure. Medicine (Baltimore). 2016;95(24):e3912.CrossRef
66.
Vassiliou VS, Patel HC, Rosen SD, Auger D, Hayward C, Alpendurada F, et al. Left atrial dilation in patients with heart failure and preserved ejection fraction: insights from cardiovascular magnetic resonance. Int J Cardiol. 2016;210:158–60.PubMedCrossRef
67.
Rossi A, Gheorghiade M, Triposkiadis F, Solomon SD, Pieske B, Butler J. Left atrium in heart failure with preserved ejection fraction: structure, function, and significance. Circ Heart Fail. 2014;7(6):1042–9.PubMedCrossRef
68.
69.
Kellman P, Wilson JR, Xue H, Ugander M, Arai AE. Extracellular volume fraction mapping in the myocardium, part 1: evaluation of an automated method. J Cardiovasc Magn Reson. 2012;14:63.PubMedPubMedCentralCrossRef
70.
Nakamori S, Dohi K, Ishida M, Goto Y, Imanaka-Yoshida K, Omori T, et al. Native T1 mapping and extracellular volume mapping for the assessment of diffuse myocardial fibrosis in dilated cardiomyopathy. JACC Cardiovasc Imaging. 2018;11(1):48–59.PubMedCrossRef
71.
Moustafa A, Khan MS, Alsamman MA, Jamal F, Atalay MK. Prognostic significance of T1 mapping parameters in heart failure with preserved ejection fraction: a systematic review. Heart Fail Rev. 2021;26(6):1325–31.PubMedCrossRef
72.
Roy C, Slimani A, de Meester C, Amzulescu M, Pasquet A, Vancraeynest D, et al. Associations and prognostic significance of diffuse myocardial fibrosis by cardiovascular magnetic resonance in heart failure with preserved ejection fraction. J Cardiovasc Magn Reson. 2018;20(1):55.PubMedPubMedCentralCrossRef
73.
Jeong D, Lee MA, Li Y, Yang DK, Kho C, Oh JG, et al. Matricellular protein CCN5 reverses established cardiac fibrosis. J Am Coll Cardiol. 2016;67(13):1556–68.PubMedPubMedCentralCrossRef
74.
Schelbert EB, Sabbah HN, Butler J, Gheorghiade M. Employing extracellular volume cardiovascular magnetic resonance measures of myocardial fibrosis to foster novel therapeutics. Circ Cardiovasc Imaging. 2017;10(6):e005619.
75.
Haji K, Marwick TH. Clinical utility of echocardiographic strain and strain rate measurements. Curr Cardiol Rep. 2021;23(3):18.PubMedCrossRef
76.
Kraigher-Krainer E, Shah AM, Gupta DK, Santos A, Claggett B, Pieske B, et al. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2014;63(5):447–56.PubMedCrossRef
77.
Chirinos JA, Orlenko A, Zhao L, Basso MD, Cvijic ME, Li Z, et al. Multiple plasma biomarkers for risk stratification in patients with heart failure and preserved ejection fraction. J Am Coll Cardiol. 2020;75(11):1281–95.PubMedPubMedCentralCrossRef
78.
Carnes J, Gordon G. Biomarkers in heart failure with preserved ejection fraction: an update on progress and future challenges. Heart Lung Circ. 2020;29(1):62–8.PubMedCrossRef
79.
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200.PubMedCrossRef
80.
81.
House AA, Wanner C, Sarnak MJ, Piña IL, McIntyre CW, Komenda P, et al. Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019;95(6):1304–17.PubMedCrossRef
82.
Sepehri Shamloo A, Bollmann A, Dagres N, Hindricks G, Arya A. Natriuretic peptides: biomarkers for atrial fibrillation management. Clin Res Cardiol. 2020;109(8):957–66.PubMedCrossRef
83.
Myhre PL, Vaduganathan M, Claggett B, Packer M, Desai AS, Rouleau JL, et al. B-type natriuretic peptide during treatment with sacubitril/valsartan: thePARADIGM-HF Trial. J Am Coll Cardiol. 2019;73(11):1264–72.PubMedPubMedCentralCrossRef
84.
Duca F, Kammerlander AA, Zotter-Tufaro C, Aschauer S, Schwaiger ML, Marzluf BA, et al. Interstitial fibrosis, functional status, and outcomes in heart failure with preserved ejection fraction: insights from a prospective cardiac magnetic resonance imaging study. Circ Cardiovasc Imaging. 2016;9(12):e005277.
85.
Pandey A, Golwala H, Sheng S, DeVore AD, Hernandez AF, Bhatt DL, et al. Factors associated with and prognostic implications of cardiac troponin elevation in decompensated heart failure with preserved ejection fraction: findings from the American Heart Association Get With The Guidelines-Heart Failure Program. JAMA Cardiol. 2017;2(2):136–45.PubMedCrossRef
86.
Tona F, Montisci R, Iop L, Civieri G. Role of coronary microvascular dysfunction in heart failure with preserved ejection fraction. Rev Cardiovasc Med. 2021;22(1):97–104.PubMedCrossRef
87.
Kamimura D, Suzuki T, Furniss AL, Griswold ME, Kullo IJ, Lindsey ML, et al. Elevated serum osteoprotegerin is associated with increased left ventricular mass index and myocardial stiffness. J Cardiovasc Med (Hagerstown). 2017;18(12):954–61.CrossRef
88.
Gohar A, Chong JPC, Liew OW, den Ruijter H, de Kleijn DPV, Sim D, et al. The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction. Eur J Heart Fail. 2017;19(12):1638–47.PubMedCrossRef
89.
AbouEzzeddine OF, Haines P, Stevens S, Nativi-Nicolau J, Felker GM, Borlaug BA, et al. Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure). JACC Heart Fail. 2015;3(3):245–52.PubMedPubMedCentralCrossRef
90.
Zile MR, Jhund PS, Baicu CF, Claggett BL, Pieske B, Voors AA, et al. Plasma biomarkers reflecting profibrotic processes in heart failure with a preserved ejection fraction: data from the Prospective Comparison of ARNI with ARB on Management of Heart Failure with Preserved Ejection Fraction Study. Circ Heart Fail. 2016;9(1):e002551.
91.
Albar Z, Albakri M, Hajjari J, Karnib M, Janus SE, Al-Kindi SG. Inflammatory markers and risk of heart failure with reduced to preserved ejection fraction. Am J Cardiol. 2022;167:68–75.PubMedCrossRef
92.
Angraal S, Mortazavi BJ, Gupta A, Khera R, Ahmad T, Desai NR, et al. Machine learning prediction of mortality and hospitalization in heart failure with preserved ejection fraction. JACC Heart Fail. 2020;8(1):12–21.PubMedCrossRef
93.
• Sanders WE, Burton T, Khosousi A, Ramchandani S. Machine learning: at the heart of failure diagnosis. Curr Opin Cardiol. 2021;36(2):227–33. Provide study using unsupervised ML methods of similar clinical markers as Cohen et al.PubMedCrossRef
94.
• Greener JG, Kandathil SM, Moffat L, Jones DT. A guide to machine learning for biologists. Nat Rev Mol Cell Biol. 2022;23(1):40–55. Provide first phenotype study using ML methods for solely Asian patients with HFpEF.PubMedCrossRef
95.
• Ramspek CL, Jager KJ, Dekker FW, Zoccali C, van Diepen M. External validation of prognostic models: what, why, how, when and where? Clin Kidney J. 2021;14(1):49–58. Provide LCA on HFpEF patients from a large cohort with external validation on a geographically distinct cohort.PubMedCrossRef
96.
Adamczak DM, Oduah MT, Kiebalo T, Nartowicz S, Bęben M, Pochylski M, et al. Heart failure with preserved ejection fraction-a concise review. Curr Cardiol Rep. 2020;22(9):82.PubMedPubMedCentralCrossRef
97.
Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015;131(1):34–42.PubMedCrossRef
98.
Woolley RJ, Ceelen D, Ouwerkerk W, Tromp J, Figarska SM, Anker SD, et al. Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction. Eur J Heart Fail. 2021;23(6):983–91.PubMedCrossRef
99.
Gu J, Pan JA, Lin H, Zhang JF, Wang CQ. Characteristics, prognosis and treatment response in distinct phenogroups of heart failure with preserved ejection fraction. Int J Cardiol. 2021;323:148–54.PubMedCrossRef
100.
Uijl A, Savarese G, Vaartjes I, Dahlström U, Brugts JJ, Linssen GCM, et al. Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction. Eur J Heart Fail. 2021;23(6):973–82.PubMedCrossRef
101.
Hedman Å, Hage C, Sharma A, Brosnan MJ, Buckbinder L, Gan LM, et al. Identification of novel pheno-groups in heart failure with preserved ejection fraction using machine learning. Heart. 2020;106(5):342–9.PubMedCrossRef
102.
Segar MW, Patel KV, Ayers C, Basit M, Tang WHW, Willett D, et al. Phenomapping of patients with heart failure with preserved ejection fraction using machine learning-based unsupervised cluster analysis. Eur J Heart Fail. 2020;22(1):148–58.PubMedCrossRef
103.
Elkholey K, Papadimitriou L, Butler J, Thadani U, Stavrakis S. Effect of obesity on response to spironolactone in patients with heart failure with preserved ejection fraction. Am J Cardiol. 2021;146:36–47.PubMedPubMedCentralCrossRef
104.
Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609–20.PubMedCrossRef
105.
Anker SD, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, et al. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. Eur J Heart Fail. 2019;21(10):1279–87.PubMedCrossRef
106.
Packer M. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis. Diabetes Obes Metab. 2018;20(6):1361–6.PubMedCrossRef
107.
Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, et al. Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced Trial. Circulation. 2021;143(4):326–36.PubMedCrossRef
108.
109.
Tabucanon T, Wilcox J, Tang WHW. Does weight loss improve clinical outcomes in overweight and obese patients with heart failure? Curr Diab Rep. 2020;20(12):75.PubMedCrossRef
110.
Rodriguez Flores M, Aguilar Salinas C, Piché ME, Auclair A, Poirier P. Effect of bariatric surgery on heart failure. Expert Rev Cardiovasc Ther. 2017;15(8):567–79.PubMedCrossRef
111.
Leonard B, Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev. 2012;36(2):764–85.PubMedCrossRef
112.
Koepp KE, Obokata M, Reddy YNV, Olson TP, Borlaug BA. Hemodynamic and functional impact of epicardial adipose tissue in heart failure with preserved ejection fraction. JACC Heart Fail. 2020;8(8):657–66.PubMedPubMedCentralCrossRef
113.
Tsujimoto T, Kajio H. Abdominal obesity is associated with an increased risk of all-cause mortality in patients with HFpEF. J Am Coll Cardiol. 2017;70(22):2739–49.PubMedCrossRef
114.
Tadic M, Sala C, Saeed S, Grassi G, Mancia G, Rottbauer W, et al. New antidiabetic therapy and HFpEF: light at the end of tunnel? Heart Fail Rev. 2022;27(4):1137–46.PubMedCrossRef
115.
Bonnefoy M, Gilbert T. Body composition and comorbidity in the elderly. Geriatr Psychol Neuropsychiatr Vieil. 2015;13(Suppl 1):29–36.PubMed
116.
117.
Odajima S, Tanaka H, Fujimoto W, Kuroda K, Yamashita S, Imanishi J, et al. Efficacy of Renin-angiotensin-aldosterone-system inhibitors for heart failure with preserved ejection fraction and left ventricular hypertrophy -from the KUNIUMI Registry Acute Cohort. J Cardiol. 2022;79(6):703–10.PubMedCrossRef
118.
Barman TK, Roy S, Hossain SM, Salahuddin AZ, Huq MO. Comparison of cardiac outcome of continuous ambulatory peritoneal dialysis & hemodialysis in CKD5 patients with heart failure. Mymensingh Med J. 2020;29(4):793–9.PubMed
119.
Grossekettler L, Schmack B, Brockmann C, Wanninger R, Kreusser MM, Frankenstein L, et al. Benefits of peritoneal ultrafiltration in HFpEF and HFrEF patients. BMC Nephrol. 2020;21(1):179.PubMedPubMedCentralCrossRef
120.
Collins AJ, Foley R, Herzog C, Chavers B, Gilbertson D, Ishani A, et al. Excerpts from the United States Renal Data System 2007 annual data report. Am J Kidney Dis. 2008;51(1 Suppl 1):S1-320.PubMed
121.
Kjeldsen SE, von Lueder TG, Smiseth OA, Wachtell K, Mistry N, Westheim AS, et al. Medical therapies for heart failure with preserved ejection fraction. Hypertension. 2020;75(1):23–32.PubMedCrossRef
122.
Metadaten
Titel
Defining the Phenotypes for Heart Failure With Preserved Ejection Fraction
verfasst von
Dane Rucker
Jacob Joseph
Publikationsdatum
30.09.2022
Verlag
Springer US
Erschienen in
Current Heart Failure Reports / Ausgabe 6/2022
Print ISSN: 1546-9530
Elektronische ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-022-00582-x

Weitere Artikel der Ausgabe 6/2022

Current Heart Failure Reports 6/2022 Zur Ausgabe

Decompensated Heart Failure (P. Banerjee, Section Editor)

‘Acute Heart Failure’: Should We Abandon the Term Altogether?

Clinical Heart Failure (T.E. Meyer, Section Editor)

Optimization of Drug Therapy for Heart Failure With Reduced Ejection Fraction Based on Gender

Imaging in Heart Failure (J. Schulz-Menger, Section Editor)

The Electrocardiogram in the Diagnosis and Management of Patients With Left Ventricular Non-Compaction

Cardio-renal Interactions in Heart Failure (P. Martens, Section Editor)

Right Heart Function in Cardiorenal Syndrome

Clinical Heart Failure (T.E. Meyer, Section Editor)

Efficacy of ICD/CRT-D Remote Monitoring in Patients With HFrEF: a Bayesian Meta-analysis of Randomized Controlled Trials

Biomarkers of Heart Failure (W.H.W. Tang and J. Grodin, Section Editors)

Biomarkers in HFpEF for Diagnosis, Prognosis, and Biological Phenotyping

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise